Bio-Rad Laboratories, Inc. (BIO) Return on Assets (ROA): 1.72%
Is Bio-Rad Laboratories, Inc.’s return on assets (ROA) high or low?
Bio-Rad Laboratories, Inc.'s return on assets (ROA) of 1.72% is 18% above its 5-year average of 1.46%, around the middle of its 5-year range (-26.87%–29.40%).
As of Thursday, June 11, 2026. 127.50% above its 12-month average of -6.26%.
BIO Return on Assets (ROA) Chart
BIO Average Return on Assets (ROA) Chart
BIO Current vs Average Return on Assets (ROA) Chart
BIO Return on Assets (ROA) Metrics
RETURN ON ASSETS (ROA)
1.72%
RETURN ON ASSETS (ROA) AVG TTM
-6.26%
RETURN ON ASSETS (ROA) AVG 3Y
-11.14%
RETURN ON ASSETS (ROA) AVG 5Y
1.46%
RETURN ON ASSETS (ROA) AVG 10Y
3.96%
RETURN ON ASSETS (ROA) AVG 15Y
4.08%
RETURN ON ASSETS (ROA) AVG 20Y
4.39%
CURRENT VS TTM AVG
+127.50%
CURRENT VS 3Y AVG
+115.44%
CURRENT VS 5Y AVG
+18.08%
CURRENT VS 10Y AVG
-56.61%
CURRENT VS 15Y AVG
-57.85%
CURRENT VS 20Y AVG
-60.86%
BIO Competitors' Return on Assets (ROA)
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bio-Rad Laboratories, Inc. (BIO) | $7.92B | 1.72% | -6.26% | -11.14% | 1.46% |
| Charles River Laboratories International, Inc. (CRL) | $8.94B | -2.39% | -0.94% | 2.58% | 3.75% |
| Hims & Hers Health, Inc. (HIMS) | $6.19B | -0.58% | 11.88% | 0.12% | -6.73% |
| Baxter International Inc. (BAX) | $10.49B | -5.53% | -3.64% | -1.62% | 0.47% |
| Align Technology, Inc. (ALGN) | $12.27B | 6.81% | 6.68% | 6.69% | 12.75% |
| Hologic, Inc. (HOLX) | $16.97B | 5.92% | 7.45% | 8.56% | 11.79% |
| Moderna, Inc. (MRNA) | $18.71B | -27.80% | -24.02% | -10.32% | -0.33% |
| BioNTech SE (BNTX) | $22.39B | -6.03% | -3.96% | 9.16% | 17.06% |
| Mettler-Toledo International Inc. (MTD) | $22.82B | 23.85% | 25.02% | 24.63% | 23.85% |
| Waters Corporation (WAT) | $23.21B | 1.83% | 13.34% | 15.53% | 17.15% |
Asset Efficiency
ROA
1.7%
ROE
2.5%
Bio-Rad Laboratories, Inc. Return on Assets (ROA) Formula & Definition
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Bio-Rad Laboratories, Inc. Return on Assets (ROA) FAQ
- What is the return on assets (ROA) for Bio-Rad Laboratories, Inc. (BIO)?
- The return on assets (ROA) for BIO stock is 1.72%.
- Is Bio-Rad Laboratories, Inc.'s return on assets (ROA) high or low?
- Bio-Rad Laboratories, Inc.'s return on assets (ROA) of 1.72% is 18% above its 5-year average of 1.46%, around the middle of its 5-year range (-26.87%–29.40%).
- What is the TTM average return on assets (ROA) for Bio-Rad Laboratories, Inc. (BIO)?
- The TTM average return on assets (ROA) for BIO stock is -6.26%.
- What is the 3Y average return on assets (ROA) for Bio-Rad Laboratories, Inc. (BIO)?
- The 3Y average return on assets (ROA) for BIO stock is -11.14%.
- What is the 5Y average return on assets (ROA) for Bio-Rad Laboratories, Inc. (BIO)?
- The 5Y average return on assets (ROA) for BIO stock is 1.46%.
- What is the 10Y average return on assets (ROA) for Bio-Rad Laboratories, Inc. (BIO)?
- The 10Y average return on assets (ROA) for BIO stock is 3.96%.
- What is the 15Y average return on assets (ROA) for Bio-Rad Laboratories, Inc. (BIO)?
- The 15Y average return on assets (ROA) for BIO stock is 4.08%.
- What is the 20Y average return on assets (ROA) for Bio-Rad Laboratories, Inc. (BIO)?
- The 20Y average return on assets (ROA) for BIO stock is 4.39%.
Bio-Rad Laboratories, Inc. Return on Assets (ROA) History
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 7.18% |
| 2024-12-31 | -19.69% |
| 2023-12-31 | -5.18% |
| 2022-12-31 | -26.87% |
| 2021-12-31 | 23.90% |
| 2020-12-31 | 29.40% |
| 2019-12-31 | 21.96% |
| 2018-12-31 | 6.43% |
| 2017-12-31 | 2.69% |
| 2016-12-31 | 0.73% |
| 2015-12-31 | 3.05% |
| 2014-12-31 | 2.66% |
| 2013-12-31 | 2.30% |
| 2012-12-31 | 4.91% |
| 2011-12-31 | 5.76% |
| 2010-12-31 | 6.06% |
| 2009-12-31 | 5.70% |
| 2008-12-31 | 4.39% |
| 2007-12-31 | 4.72% |
| 2006-12-31 | 6.47% |
| 2005-12-31 | 5.72% |
| 2004-12-31 | 4.98% |
| 2003-12-31 | 7.67% |
| 2002-12-31 | 9.42% |
| 2001-12-31 | 6.46% |
| 2000-12-31 | 4.81% |
| 1999-12-31 | 1.75% |
| 1998-12-31 | 6.62% |
| 1997-12-31 | 4.66% |
| 1996-12-31 | 9.20% |
Related Metrics
About Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Norman D. Schwartz